Less Toxic Chemotherapy Regimen for Metastatic Urothelial Cancer Shows Promise
Less Toxic Chemotherapy Regimen for Metastatic Urothelial Cancer Shows Promise According to the results of a phase II clinical trial published in the journal Cancer, the chemotherapy combination P-HDFL...
View ArticleHigh-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and...
High-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and Radical Prostatectomy Among patients undergoing radical cystectomy (removal of bladder) or radical prostatectomy (removal of...
View ArticleGemzar® and Eloxatin® Promising for Advanced Bladder Cancer
Gemzar® and Eloxatin® Promising for Advanced Bladder Cancer According to an article recently published in the Annals of Oncology, the chemotherapy combination consisting of Eloxatin® (oxaliplatin) and...
View ArticleHerceptin® Evaluated in Advanced Bladder Cancer
Herceptin® Evaluated in Advanced Bladder Cancer According to the results of a Phase II clinical trial, Herceptin® (trastuzumab)-a targeted therapy used in the treatment of HER2-positive breast...
View ArticleUpdate on the Management of Genitourinary Malignancies
Update on the Management of Genitourinary Malignancies: A Report from the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) Kidney cancer, the orphan disease that had only one...
View ArticleCancer Caregivers Devote Substantial Time and Effort
On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer. Informal caregiving is an important part of cancer...
View ArticleStudy Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in...
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall...
View ArticleLiposomal Cisplatin Safe for Patients with Renal Insufficiency
Liposomal cisplatin (Nanoplatin®), a chemotherapy drug still in clinical trials, does not cause damage to the kidneys and appears to provide at least equal anti-cancer effects as cisplatin (Platinol®)...
View ArticleAdding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence
Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, according to the results of a study published in the New...
View ArticleFactors Affecting Quality of Life at the End of Life
For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance with...
View ArticleRobotic Bladder Cancer Surgery Safe and Effective
Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a...
View ArticleStrategies to Improve Treatment
The progress that has been made in the treatment of bladder cancer has resulted from improved treatments evaluated in clinical trials. Future progress in the treatment of bladder cancer will result...
View ArticleExperimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer
According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of...
View ArticleSurvival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer
Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the...
View ArticleCyramza® plus Taxotere® Promising in Advanced Bladder Cancer
The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous...
View ArticleDurvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death...
View ArticleTecentriq® Effective as Initial Therapy in Advanced Bladder Cancer
The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy....
View ArticleTecentriq® Approved for Bladder Cancer
The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1...
View ArticleKeytruda Immunotherapy Improves Overall Survival in Bladder Cancer
Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average age that patients are diagnosed with bladder cancer is 70 years, with 80% of these...
View ArticleAdding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence
Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, […] The post Adding Chemotherapy to Radiation Reduces...
View Article
More Pages to Explore .....